Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 3 4Phase 2 3

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 98Lymphoma 79Burkitt Lymphoma 52Leukemia, Myeloid, Acute 51Myelodysplastic Syndromes 41Lymphoma, Non-Hodgkin 41Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Mantle-Cell 33Leukemia, Lymphocytic, Chronic, B-Cell 32Leukemia, Myeloid, Accelerated Phase 30Hodgkin Disease 29Lymphoma, Follicular 28Blast Crisis 27Graft vs Host Disease 26Congenital Abnormalities 26Myeloproliferative Disorders 25Leukemia, Myeloid, Chronic-Phase 25Multiple Myeloma 24Breast Neoplasms 23Lymphoma, B-Cell, Marginal Zone 22Leukemia, Myelomonocytic, Chronic 22Lymphoma, Large-Cell, Immunoblastic 21Primary Myelofibrosis 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 16Recurrence 15Neoplasms, Plasma Cell 15Dendritic Cell Sarcoma, Interdigitating 15Anemia, Refractory, with Excess of Blasts 15

Interventions

Methotrexate 3olokizumab 2veltuzumab 1upadacitinib 1tocilizumab 1mavrilimumab 1golimumab 1andecaliximab 1Vaccines 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Saline Solution 1RC-18 1Interleukin 1 Receptor Antagonist Protein 1ISIS104838 1Herpes Zoster Vaccine 1Bortezomib 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Arthritis, Rheumatoid × Methotrexate × Clear all
NCT03001219 2020-01-29

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Hoffmann-La Roche

Phase 2 Terminated
109 enrolled 24 charts

Arthritis, Rheumatoid

NCT02882087 2019-04-03

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

RemeGen Co., Ltd.

Phase 2 Terminated
60 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

NCT02862574 2018-06-27

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Gilead Sciences

Phase 2 Terminated
15 enrolled 11 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡